In support of BBB disruption’s influence on cognitive impairment, a recent work suggested that BBB breakdown takes part in APOE4-connected cognitive weakening independently of AD pathology and might be a therapeutic target in APOE4 carriers [108]. This evidence concerns the gene APOE and Cognitive impairment.